Cargando…

FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway

OBJECTIVE: To study the expression, biological function, and mechanism of FKBP4 in non-small-cell lung cancer (NSCLC). METHODS: First of all, the expression of FKBP4 in NSCLC tissues and cell lines was detected by qRT-PCR; then, the effects of FKBP4 on proliferation, apoptosis, migration, and invasi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Wen, Meng, Jingfei, Jiang, Hong, Feng, Xing, Wei, Dongshan, Ding, Qingsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737458/ https://www.ncbi.nlm.nih.gov/pubmed/33354489 http://dx.doi.org/10.1155/2020/6021602

Ejemplares similares

GTSE1 Facilitates the Malignant Phenotype of Lung Cancer Cells via Activating AKT/mTOR Signaling
por: Zhang, Fan, et al.
Publicado: (2021)

An evaluation tool for FKBP12-dependent and -independent mTOR inhibitors using a combination of FKBP-mTOR fusion protein, DSC and NMR
por: Sekiguchi, Mitsuhiro, et al.
Publicado: (2011)

Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions
por: Nasr, Arash Boroumand, et al.
Publicado: (2015)

Alpha-synuclein contributes to malignant progression of human meningioma via the Akt/mTOR pathway
por: Ge, Yiqin, et al.
Publicado: (2016)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Akt/mTOR Targeting Activity of Resveratrol Derivatives in Non-Small Lung Cancer
por: Innets, Bhurichaya, et al.
Publicado: (2022)

Rapamycin recruits SIRT2 for FKBP12 deacetylation during mTOR activity modulation in innate immunity
por: Hu, Lin, et al.
Publicado: (2021)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
por: Lisi, Lucia
Publicado: (2020)

EDG2 enhanced the progression of hepatocellular carcinoma by LPA/PI3K/AKT/ mTOR signaling
por: Xu, Meng, et al.
Publicado: (2017)

Curcumol inhibits the malignant progression of prostate cancer and regulates the PDK1/AKT/mTOR pathway by targeting miR-9
por: Sheng, Wen, et al.
Publicado: (2021)

Mechanically activated ion channel Piezo1 contributes to melanoma malignant progression through AKT/mTOR signaling
por: Zhang, Simei, et al.
Publicado: (2022)

Akt and mTOR in B Cell Activation and Differentiation
por: Limon, Jose J., et al.
Publicado: (2012)

Akt and mTOR mediate programmed necrosis in neurons
por: Liu, Q, et al.
Publicado: (2014)

Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations
por: Krencz, Ildiko, et al.
Publicado: (2021)

Isoflurane Promotes Non-Small Cell Lung Cancer Malignancy by Activating the Akt-Mammalian Target of Rapamycin (mTOR) Signaling Pathway
por: Zhang, Wenhua, et al.
Publicado: (2016)

mTOR Regulation of Metabolism in Hematologic Malignancies
por: Mirabilii, Simone, et al.
Publicado: (2020)

Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2020)

Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs: Effect of Akt/mTOR inhibition on PTEN expression
por: Wan, Linyan, et al.
Publicado: (2022)

Interaction of YAP1 and mTOR promotes bladder cancer progression
por: Xu, Mingxi, et al.
Publicado: (2019)

The Local Anesthetic Bupivacaine Inhibits the Progression of Non-Small Cell Lung Cancer by Inducing Autophagy Through Akt/mTOR Signaling
por: Gu, Jian-Hua, et al.
Publicado: (2021)

TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4
por: Wei, Chuan-Yuan, et al.
Publicado: (2019)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

AKT phosphorylation as a predictive biomarker for PI3K/mTOR dual inhibition-induced proteolytic cleavage of mTOR companion proteins in small cell lung cancer
por: Hung, Ming-Chun, et al.
Publicado: (2022)

GPR41 Regulates the Proliferation of BRECs via the PIK3-AKT-mTOR Pathway
por: Meng, Zitong, et al.
Publicado: (2023)

UNBS5162 and amonafide inhibits tumor progression in human melanoma by the AKT/mTOR pathway
por: Ye, Yingyi, et al.
Publicado: (2019)

TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway
por: Xiong, Dian, et al.
Publicado: (2018)

GABARAP suppresses EMT and breast cancer progression via the AKT/mTOR signaling pathway
por: Liu, Ying, et al.
Publicado: (2021)

Zyxin promotes hepatocellular carcinoma progression via the activation of AKT/mTOR signaling pathway
por: CAI, TIANYING, et al.
Publicado: (2023)

PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities
por: Wiese, Wojciech, et al.
Publicado: (2023)

Profiling of Phospho-AKT, Phospho-mTOR, Phospho-MAPK and EGFR in Non-small Cell Lung Cancer
por: Kitano, Haruhisa, et al.
Publicado: (2014)

Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)
por: Tan, Aaron C.
Publicado: (2020)

Involvement of Akt/mTOR in the Neurotoxicity of Rotenone-Induced Parkinson’s Disease Models
por: Zhang, Yu, et al.
Publicado: (2019)

HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN/AKT/mTOR pathway
por: Zheng, Yawen, et al.
Publicado: (2020)

PSME4 Activates mTOR Signaling and Promotes the Malignant Progression of Hepatocellular Carcinoma
por: Ge, Sijia, et al.
Publicado: (2022)

ESM1 promotes angiogenesis in colorectal cancer by activating PI3K/Akt/mTOR pathway, thus accelerating tumor progression
por: Yang, Liqun, et al.
Publicado: (2023)

Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4
por: Zhu, Meng-Xuan, et al.
Publicado: (2019)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

TTI1 promotes non‐small‐cell lung cancer progression by regulating the mTOR signaling pathway
por: Zhang, Ling‐Xian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2ilpf2c6uqt0aapovab20kl5s9